BIOMM

What BIOMM does

Biomm S.A. (B3: BIOM3) is a 100% Brazilian, publicly traded biotechnology company that develops, manufactures, and commercializes biomedicines for chronic diseases, with a focus on diabetes, oncology, ophthalmology, and thromboembolism. The company was created in 2001 as a spin-off of Biobrás (which was acquired by Novo Nordisk), inheriting recombinant human insulin production know-how, the original research team, and a USPTO-granted recombinant insulin patent from 2000. Biomm operates a US$90 million biopharmaceutical manufacturing facility in Nova Lima, Minas Gerais, with 20 million vials/year of insulin and analogue capacity, validated for vaccine and biologic production. The company operates a portfolio of ANVISA-approved products including Glargilin (insulin glargine — first nationally produced in Brazil), Wosulin N/R (human insulin), Afrezza (inhaled insulin), Herzuma (trastuzumab, now 100% commercialized by Celltrion since January 2025), Bevyx (bevacizumab), Ghemaxan (enoxaparin, approved in 22 countries), and Ranivisio (ranibizumab biosimilar, ANVISA-approved May 2025, launched April 2026).

The company's revenue model is bimodal. In the public market, Biomm supplies the SUS (Brazil's Unified Health System) through Productive Development Partnerships (PDPs) with Fiocruz/Bio-Manguinhos and Fundação Ezequiel Dias (Funed), distributing Wosulin and insulin glargine. In the private market, Biomm distributes through national pharmacy chains and distributors, anchored by Glargilin sales. The go-to-market relies on a direct sales representative field force, an SAC call center (0800-0572466), and digital channels (Scientific Portal, YouTube, Spotify podcasts). Exclusive licensing partnerships with Gan & Lee (China), Bioton (Poland), MannKind (USA), Celltrion (South Korea), Bioeq (Switzerland), and CanSino (China) provide Biomm access to originator biologic IP for Brazilian commercialization, with potential to manufacture locally.

Biomm reported Q1 2026 net revenue of R$92.5 million (134% YoY growth from R$39.5M in Q1 2025), a net profit of R$9.7 million (reversing a R$11.7M loss), and EBITDA of R$12.4 million (reversing negative R$10.7M). Management has established a 2026 EBITDA target of R$90–100 million. Major shareholders include Alaska Investimentos (26.15%), BTGP Gestão (12.20%), SAMOS/WMG (8.24%), TMG/IBR (7.25%), BNDESPAR (5.12%), and Grupo Ítalo (5.10%). The company has raised R$459.6 million across five capital increases from 2021 to 2025.

Name

BIOMM

Legal name

BIOMM S.A.

Website

https://biomm.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

Biomm S.A. is a Brazilian biotechnology company that develops, manufactures, and commercializes biosimilars and biomedicines for diabetes, oncology, ophthalmology, and thromboembolism, serving both the public SUS market and private pharmacy chains in Brazil.

Ownership category

akta.pro rank

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIAFAB

Insulin & Analog Biosimilars

Healthcare & Life Sciences/Pharmaceuticals/Biosimilars

SECONDARYHLAIAAAE

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIACAO

Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Biopharmaceutical manufacturing
• Biosimilar medicines
• Recombinant insulin
• Monoclonal antibody therapy
• Biological drugs

Headquarters

HQ city

Nova Lima

HQ country

Brazil

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Biomedicines Importation and Commercialization: Revenue primarily from importing and commercializing biotechnological medicines. Currently driven by insulin sales — Wosulin (human insulin) for the public market and Glargilin (insulin glargine) for the private market. Growth from 134% revenue increase in Q1 2026 to R$92.5M net revenue. Company is transitioning from import-only to national production.
2. Licensed Product Partnerships: Biomm commercializes products under exclusive licensing agreements with international partners: Gan & Lee (China) and Bioton (Poland) for diabetes; MannKind Corp (USA) for Afrezza inhalable insulin; Celltrion Healthcare (South Korea) for oncology (Herzuma trastuzumab, Bevyx bevacizumab); CanSino Biologics (China) for Convidecia vaccine. Revenue model is commercializing licensed biologics in Brazil, with potential for local production under the same agreements.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

BIOMM develops, manufactures, and commercializes biomedicines including recombinant insulins (human insulin NPH and regular, insulin glargine, and the inhalable insulin Afrezza), biosimilar monoclonal antibodies (Bevacizumab/Bevyx, Trastuzumab/Herzuma), and specialty injectables such as Enoxaparin (Ghemaxan) and Ranibizumab (Ranivisio). The company also supplies insulin delivery pens (Lifepen G and Biopemm). Products are sold under its own brand portfolio to the Brazilian public health system (SUS) through PDPs and to private-market distributors, hospital networks, and pharmacy chains.

Product overview

BIOMM is a Brazilian biotechnology company that develops, manufactures, and commercializes biomedicines. The company operates two main product portfolios: (1) Diabetes treatments including insulins (Glargilin, Wosulin N, Wosulin R, Afrezza) and insulin delivery devices (Lifepen G and Biopemm insulin pens); and (2) Hospital and Oncology products including monoclonal antibodies for cancer treatment (Bevyx/Bevacizumabe, Herzuma/Trastuzumab), anticoagulants (Ghemaxan/Enoxaparin), and ophthalmology treatments (Ranivisio/Ranibizumab). BIOMM is 100% nationally owned and operates its manufacturing facility in Nova Lima, Minas Gerais, producing insulin glargine domestically for the first time in Brazil.

Differentiator

Problem solved

Functional benefit

Products and services

• Wosulin N Recombinant human insulin NPH (intermediate-acting), an injectable basal insulin for glycemic control in patients with type 1 and type 2 diabetes, prescribed by endocrinologists and diabetologists and supplied through SUS and private pharmacies.
• Wosulin R Recombinant human insulin regular (rapid-acting) injectable for prandial glycemic control in diabetes mellitus patients, used in hospitals and outpatient settings.
• Glargilin Insulin glargine (long-acting basal insulin analog) for once-daily glycemic control in type 1 and type 2 diabetes, positioned as a domestic alternative to imported basal insulins.
• Afrezza Inhalable (pulmonary) rapid-acting insulin for prandial glycemic control in adults with diabetes, offering a needle-free administration alternative to injectable prandial insulins.
• Bevyx (Bevacizumabe) Bevacizumab biosimilar — anti-VEGF monoclonal antibody used in oncology for metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, ovarian cancer, and renal cell carcinoma, supplied to SUS and private oncology centers.
• Herzuma (Trastuzumabe) Trastuzumab biosimilar — anti-HER2 monoclonal antibody for HER2-positive breast cancer and metastatic gastric cancer, used in hospital oncology and outpatient infusion settings.
• Ghemaxan (Enoxaparina) Enoxaparin biosimilar — low-molecular-weight heparin (LMWH) anticoagulant for prevention and treatment of deep vein thrombosis, pulmonary embolism, and acute coronary syndromes, supplied to hospitals and SUS.
• Ranivisio (Ranibizumabe) Ranibizumab biosimilar — anti-VEGF monoclonal antibody fragment administered by intravitreal injection for neovascular (wet) age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, sold to ophthalmology clinics and SUS.
• Caneta Lifepen G Reusable insulin delivery pen designed for use with BIOMM insulin cartridges, supporting diabetes patients with ergonomic, multi-dose insulin administration.
• Caneta Biopemm BIOMM-branded insulin pen for subcutaneous delivery of BIOMM insulins, providing a convenient multi-dose administration device for diabetes patients.

Quantifiable outcome

• Q1 2026 net revenue of R$92.5M, a 134% increase year-over-year, driven by insulin sales growth.
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Fiocruz / Bio-ManguinhoscoreStrategic or Co-development Partner · 1 January 2026Productive Development Partnership (PDP) for insulin glargine production. Biomm contributes national manufacturing capability at Nova Lima plant; Fiocruz/Bio-Manguinhos supports public health system supply for SUS.
• Fundação Ezequiel Dias (Funed)coreStrategic or Co-development Partner · 1 January 2026Productive Development Partnership (PDP) for insulin glargine. Funed, a public pharmaceutical foundation in Minas Gerais, collaborates with Biomm for local insulin production to serve the Brazilian public health system.
• Bioeq (Switzerland)coreStrategic or Co-development Partner · 1 January 2025Collaboration with Swiss biotech Bioeq for development of biosimilar ranibizumab (Ranivisio). Bioeq contributes international biosimilar development expertise; Biomm handles Brazilian regulatory approval (ANVISA, May 2025) and commercialization. Ranivisio blocks VEGF for retinal disease treatment.
• CanSino Biologics INCcoreStrategic or Co-development Partner · 1 October 2021Agreement to supply Convidecia single-dose COVID-19 vaccine in Brazil. Biomm to submit emergency use authorization to ANVISA and potentially manufacture locally at the Nova Lima plant (which received US$90M investment). Agreement also covers the full CanSino vaccine portfolio. Convidecia uses adenovirus type 5 vector, stored at 2-8°C, with 68.83% overall efficacy.
• CytoDyn (USA)minorStrategic or Co-development Partner · 1 January 2021Exclusive partner for commercialization of Leronlimabe in Brazil — a monoclonal antibody developed for COVID-19 hospitalized patients requiring oxygen support. ANVISA approved Phase 3 clinical studies in August-September 2021, conducted by ARO of Hospital Israelita Albert Einstein.
• MannKind Corp (USA)coreStrategic or Co-development Partner · 1 January 2017Exclusive partnership for commercialization of Afrezza (inhaled insulin) in Brazil. Afrezza is a rapid-acting inhaled insulin approved for diabetes treatment, launched in Brazil in 2019.
• Celltrion Healthcare (South Korea)coreStrategic or Co-development Partner · 1 January 2017Exclusive partnership for commercialization of oncology treatments in Brazil. Covers Herzuma (trastuzumab, biosimilar for HER2+ breast cancer) and potentially other monoclonal antibody oncology products. Note: Herzuma is now commercialized 100% by Celltrion since January 1, 2025.
• Gan & Lee (China)coreStrategic or Co-development Partner · 1 January 2014Exclusive partnership for commercialization of diabetes products in Brazil. Gan & Lee is a Chinese pharmaceutical company specializing in insulin and insulin analogues.
• Bioton (Poland)coreStrategic or Co-development Partner · 1 January 2014Exclusive partnership for commercialization of diabetes products in Brazil. Bioton is a Polish biotech company focused on recombinant human insulin production.

Scale indicators16 records

Recent moves13 records

Expansion highlights10 records

Direct peers

• Cristália: Brazilian pharmaceutical company with a domestic insulin and biologics manufacturing footprint, competing with Biomm in the Brazilian diabetes and hospital specialty markets.
• Samsung Bioepis: South Korean biosimilar developer and manufacturer of monoclonal antibody biosimilars (including ranibizumab, bevacizumab, trastuzumab equivalents) — directly comparable as a focused biosimilar platform.
• Biocon: India-based global biopharmaceutical company with a leading biosimilars portfolio including recombinant human insulin and insulin analogues, oncology monoclonal antibodies (trastuzumab, bevacizumab), and other biologics — closely matching Biomm's therapeutic verticals and biosimilar commercial model.
• Celltrion Healthcare: South Korean biosimilar powerhouse commercializing Herzuma (trastuzumab) and other oncology mAbs — and an existing Biomm partner. Directly comparable in biosimilar development and international commercialization of biologics.

Broad incumbents

• Hypera Pharma: Largest Brazilian pharma by revenue (B3-listed as HYPE3) with broad branded generic and specialty portfolio across multiple therapeutic areas — comparable as a domestic Brazilian pharma distribution and commercialization platform.
• Eurofarma: Brazilian multinational pharmaceutical company with broad branded generic, oncology, and hospital specialty portfolios across LATAM — comparable scale, distribution footprint, and Brazilian-market focus.
• EMS: Brazil's largest pharmaceutical company by units sold, with broad branded generics, specialty, and hospital portfolios — comparable as a major Brazilian pharma with strong private-channel distribution.
• Aché Laboratórios: Brazilian pharmaceutical company with branded specialty, generics, and consumer health products — comparable mid-to-large Brazilian pharma with overlapping primary-care and specialty portfolios.

Emerging players

• Torrent Pharmaceuticals: Indian multinational pharma with growing branded generics, biosimilars, and emerging-market focus — comparable as an emerging-market biosimilar and specialty therapeutics company.

Regional players

• Aspen Pharmacare: South African multinational pharmaceutical company with branded specialty, hospital, and biosimilar products across emerging markets — comparable as an emerging-market regional pharma with biologics exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC1wI0mFzebAiUDttrWlsTHw/videos

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOMM